The purpose of this observational registry is to evaluate the safety and performance of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical used in laparoscopic RYGB surgery to create anastomoses. The goal of the study will be achieved by assessing the device performance and reporting of peri- and postoperative complications in a prospectively maintained database.
Study Type
OBSERVATIONAL
Enrollment
150
Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
AZ Sint-Jan Brugge
Bruges, West Flanders, Belgium
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with peri-operative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at index-procedure
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with post-operative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at discharge, up to 1 week
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with post-operative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at 6 weeks follow-up
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with post-operative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at 6 months follow-up
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with postoperative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at 12 months follow-up
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of participants with post-operative anastomotic leaks and intraluminal/intraperitoneal bleeding.
Time frame: at 24 months follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To evaluate the performance of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Number of procedures with technical success, defined as laparoscopic Roux-en-Y gastric bypass formation as intended without technical difficulties and without conversion to open laparotomy.
Time frame: at index-procedure
To evaluate the performance of the easyEndoTM Universal Linear Cutting
Assessment of device performance (e.g. sharpness of the blade, staple-line formation, etc.).
Time frame: at index-procedure
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with peri-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at index-procedure
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with post-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at discharge, up to 1 week
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with post-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at 6 weeks follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with post-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at 6 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with post-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at 12 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with post-operative complications such as but not limited to: peritonitis, anastomotic stenosis/stricture, internal hernia, small bowel obstruction, ulceration, fistula formation, ventral hernia, iatrogenic splenic injury, wound infection, pneumonia, pulmonary embolism, kidney failure, gallstones, arrhythmia, stroke, infarction, death.
Time frame: at 24 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with bariatric surgery related re-interventions since the laparoscopic RYGB procedure.
Time frame: at discharge, up to 1 week
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with bariatric surgery related re-interventions since the laparoscopic RYGB procedure.
Time frame: at 6 weeks follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with bariatric surgery related re-interventions since the laparoscopic RYGB procedure.
Time frame: at 6 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with bariatric surgery related re-interventions since the laparoscopic RYGB procedure.
Time frame: at 12 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Number of participants with bariatric surgery related re-interventions since the laparoscopic RYGB procedure.
Time frame: at 24 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Change of patient's weight
Time frame: at 6 weeks follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Change of patient's weight
Time frame: at 6 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Change of patient's weight
Time frame: at 12 months follow-up
To evaluate the efficacy of the laparoscopic RYGB surgery
Change of patient's weight
Time frame: at 24 months follow-up